SynBiotic SE

XETRA SBX.DE

SynBiotic SE Gross Profit for the year ending December 31, 2023: USD 1.66 M

SynBiotic SE Gross Profit is USD 1.66 M for the year ending December 31, 2023, a -56.50% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • SynBiotic SE Gross Profit for the year ending December 31, 2022 was USD 3.82 M, a -35.44% change year over year.
  • SynBiotic SE Gross Profit for the year ending December 31, 2021 was USD 5.92 M, a 29.62% change year over year.
  • SynBiotic SE Gross Profit for the year ending December 31, 2020 was USD 4.57 M, a 0.00% change year over year.
  • SynBiotic SE Gross Profit for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
SV Wall Street
XETRA: SBX.DE

SynBiotic SE

CEO Mr. Daniel Kruse
IPO Date Jan. 7, 2021
Location Germany
Headquarters Innere Wiener Str. 14
Employees 55
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.

StockViz Staff

January 28, 2025

Any question? Send us an email